Publications by authors named "A Mintz"

Peripheral arterial disease (PAD) represents one of the most prevalent cardiovascular disease processes and carries a high burden of morbidity and mortality. Patients with chronic limb-threatening ischemia (CLTI), the most severe manifestation of PAD, have the highest rates of cardiovascular morbidity and mortality of the overall PAD population. Patients with below-the-knee (BTK) PAD have an increased propensity toward CLTI due to small-vessel caliber and the frequently comorbid conditions of end-stage renal disease and diabetes mellitus, which tend to affect small artery beds preferentially.

View Article and Find Full Text PDF
Article Synopsis
  • Focused ultrasound (FUS) combined with microbubbles shows potential for enhancing drug delivery across the blood-brain barrier (BBB) in Alzheimer's disease, but current methods are limited by their reliance on MRI facilities or invasive procedures.
  • A pilot study evaluated a new portable system, neuronavigation-guided FUS (NgFUS), in six mild to moderate Alzheimer’s patients, using real-time mapping of microbubble activity to ensure safety and efficacy during treatment.
  • Results indicated that BBB opening was achieved in 5 out of 6 subjects, with significant correlations between cavitation dose, BBB opening volume, and increased levels of Alzheimer’s biomarkers, demonstrating the system's capability for real-time monitoring and safety in outpatient settings.
View Article and Find Full Text PDF

Introduction: Microtubule (MT) stability is crucial for proper neuronal function. Understanding MT dysregulation is critical for connecting amyloid beta (Aβ) and tau-based degenerative events and early changes in presymptomatic Alzheimer's disease (AD). Herein we present positron emission tomography (PET) imaging properties of our MT-PET radiotracer, [C]MPC-6827, in multiple established AD mouse models.

View Article and Find Full Text PDF

Small extracellular vesicles (sEVs) are naturally occurring vesicles that have the potential to be manipulated to become promising drug delivery vehicles for on-demand and gene editing. Here, we developed the modular safeEXO platform, a prototype sEV delivery vehicle that is mostly devoid of endogenous RNA and can efficaciously deliver RNA and ribonucleoprotein (RNP) complexes to their intended intracellular targets manifested by downstream biologic activity. We also successfully engineered producer cells to produce safeEXO vehicles that contain endogenous Cas9 (safeEXO-CAS) to effectively deliver efficient ribonucleoprotein (RNP)-mediated CRISPR genome editing machinery to organs or diseased cells and .

View Article and Find Full Text PDF